Anish Thomas
Northwestern University · 595 works · 14,043 citations · h-index 58
Top works
- Cancer Statistics, 2002
- Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
- Antibody–drug conjugates for cancer therapy
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial
- Refining the treatment of NSCLC according to histological and molecular subtypes
- Cancer treatments: Past, present, and future
- Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
- Second malignancies after multiple myeloma: from 1960s to 2010s
- Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
- Targeting Topoisomerase I in the Era of Precision Medicine
- Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial
- Trends and Characteristics of Young Non-Small Cell Lung Cancer Patients in the United States
- Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
- Mutations of epigenetic regulatory genes are common in thymic carcinomas
- Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced unresectable mesothelioma from the JAVELIN solid tumor phase Ib trial: Safety, clinical activity, and PD-L1 expression.
- Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti–PD-L1 Antibody Avelumab
- Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy
- Colonic Necrosis Due to Oral Kayexalate in a Critically-Ill Patient
- Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma